Emily Tarco

1.2k total citations
19 papers, 620 citations indexed

About

Emily Tarco is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Emily Tarco has authored 19 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Emily Tarco's work include HER2/EGFR in Cancer Research (6 papers), Cancer Genomics and Diagnostics (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Emily Tarco is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer Genomics and Diagnostics (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Emily Tarco collaborates with scholars based in United States, India and Italy. Emily Tarco's co-authors include Nour Sneige, Funda Meric‐Bernstam, Gordon B. Mills, Argun Akçakanat, Lavinia P. Middleton, Michael T. Deavers, Ana M. González-Angulo, Huiqin Chen, Kim‐Anh Do and Carlos L. Arteaga and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Emily Tarco

19 papers receiving 606 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emily Tarco United States 14 346 332 149 145 113 19 620
Oriol Arpí Spain 15 376 1.1× 359 1.1× 149 1.0× 64 0.4× 126 1.1× 24 710
Lorenzo Castagnoli Italy 17 406 1.2× 368 1.1× 169 1.1× 120 0.8× 105 0.9× 31 726
U Vogt Germany 13 320 0.9× 293 0.9× 114 0.8× 110 0.8× 108 1.0× 32 580
Raul Ayala United States 9 356 1.0× 483 1.5× 124 0.8× 84 0.6× 253 2.2× 18 830
Yongmei Yin China 13 321 0.9× 396 1.2× 164 1.1× 69 0.5× 189 1.7× 41 733
Sofia Genta Canada 12 434 1.3× 289 0.9× 135 0.9× 66 0.5× 139 1.2× 36 742
In Ah Park South Korea 19 765 2.2× 252 0.8× 215 1.4× 95 0.7× 137 1.2× 28 1.1k
Samar Alanazi United States 8 271 0.8× 347 1.0× 66 0.4× 101 0.7× 102 0.9× 13 575
Astrid Koehler Switzerland 10 330 1.0× 316 1.0× 166 1.1× 66 0.5× 69 0.6× 15 577
Steve Guerrero United States 5 221 0.6× 431 1.3× 128 0.9× 64 0.4× 86 0.8× 6 621

Countries citing papers authored by Emily Tarco

Since Specialization
Citations

This map shows the geographic impact of Emily Tarco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Tarco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Tarco more than expected).

Fields of papers citing papers by Emily Tarco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Tarco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Tarco. The network helps show where Emily Tarco may publish in the future.

Co-authorship network of co-authors of Emily Tarco

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Tarco. A scholar is included among the top collaborators of Emily Tarco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Tarco. Emily Tarco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Akçakanat, Argun, Xiaofeng Zheng, Tae‐Beom Kim, et al.. (2021). Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research. 27(11). 3243–3252. 17 indexed citations
2.
Chakravarti, Deepavali, Christopher Terranova, Mayinuer Maitituoheti, et al.. (2019). Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nature Communications. 10(1). 1398–1398. 44 indexed citations
3.
Evans, Kurt W., Erkan Yuca, Argun Akçakanat, et al.. (2017). A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research. 23(21). 6468–6477. 48 indexed citations
4.
González-Angulo, Ana M., Ian E. Krop, Argun Akçakanat, et al.. (2015). SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 107(3). 30 indexed citations
5.
Dasari, Arvind, Alexandria T. Phan, Sanjay Gupta, et al.. (2015). Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine Related Cancer. 22(3). 431–441. 26 indexed citations
6.
Meric‐Bernstam, Funda, Argun Akçakanat, Huiqin Chen, et al.. (2014). Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. Clinical Cancer Research. 20(14). 3870–3883. 40 indexed citations
7.
8.
Sangai, Takafumi, Argun Akçakanat, Huiqin Chen, et al.. (2012). Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. Clinical Cancer Research. 18(20). 5816–5828. 124 indexed citations
9.
Sangai, Takafumi, Argun Akçakanat, Huiqin Chen, et al.. (2012). Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.. Journal of Clinical Oncology. 30(15_suppl). 1054–1054. 3 indexed citations
10.
Meric‐Bernstam, Funda, Argun Akçakanat, A. Şahin, et al.. (2012). Abstract P1-07-06: Effect of biospecimen variables on proteomic biomarker assessment in breast cancer. Cancer Research. 72(24_Supplement). P1–7. 1 indexed citations
11.
Frederick, Mitchell J., Amy J. VanMeter, Ying C. Henderson, et al.. (2011). Phosphoproteomic Analysis of Signaling Pathways in Head and Neck Squamous Cell Carcinoma Patient Samples. American Journal Of Pathology. 178(2). 548–571. 32 indexed citations
12.
13.
Gong, Yun, William H. Sweet, Larry D. Greenfield, et al.. (2009). Chromogenic In Situ Hybridization Is a Reliable Method for DetectingHER2Gene Status in Breast Cancer. American Journal of Clinical Pathology. 131(4). 490–497. 20 indexed citations
14.
Gong, Yun, William H. Sweet, Larry D. Greenfield, et al.. (2009). Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results. American Journal of Clinical Pathology. 132(2). 228–236. 16 indexed citations
15.
16.
Guo, Ming, et al.. (2007). A Human Papillomavirus Testing System in Women with Abnormal Pap Results. Acta Cytologica. 51(5). 749–754. 9 indexed citations
17.
Kawamoto, T, et al.. (2007). HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.. PubMed. 1(6). 221–7. 29 indexed citations
18.
Kawamoto, T, et al.. (2006). Amplification of HER-2/neu (erbB2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC). Journal of Clinical Oncology. 24(18_suppl). 4011–4011. 1 indexed citations
19.
Shin, Hyung Ju C., Dong M. Shin, Emily Tarco, & Nour Sneige. (2003). Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer. 99(4). 233–239. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oriol Arpí Breakdown of academic impact, for papers by Lorenzo Castagnoli Breakdown of academic impact, for papers by U Vogt Breakdown of academic impact, for papers by Raul Ayala Breakdown of academic impact, for papers by Yongmei Yin Breakdown of academic impact, for papers by Sofia Genta Breakdown of academic impact, for papers by In Ah Park Breakdown of academic impact, for papers by Samar Alanazi Breakdown of academic impact, for papers by Astrid Koehler Breakdown of academic impact, for papers by Steve Guerrero
Rankless by CCL
2026